Related references
Note: Only part of the references are listed.Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
Peter C. Taylor et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis
Hanna Kim et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Brett King et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Baricitinib in patients with moderate-tosevere atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
Fei Qi et al.
FRONTIERS IN IMMUNOLOGY (2021)
Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
Zhenpeng Dai et al.
JCI INSIGHT (2021)
Effect of Baricitinib on TPA-induced psoriasis like skin inflammation
Deepak Hiraganahalli Bhaskarmurthy et al.
LIFE SCIENCES (2021)
JAK/STAT inhibitors for the treatment of atopic dermatitis
Maria Alexandra Rodrigues et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
E. L. Simpson et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
The role of JAK/STAT signaling pathway and its inhibitors in diseases
Ping Xin et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Baricitinib-induced paradoxical psoriasis
J. Di Domizio et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
Amanda Kvist-Hansen et al.
DERMATOLOGY AND THERAPY (2020)
Repigmentation of vitiligo with oral baricitinib
Blake P. Mumford et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2020)
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis A Randomized Clinical Trial
Kristian Reich et al.
JAMA DERMATOLOGY (2020)
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Emma Guttman-Yassky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Clinical significance of Janus Kinase inhibitor selectivity (vol 58, pg 953, 2019)
Ernest H. Choy
RHEUMATOLOGY (2019)
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor
Hua Xu et al.
ACS CHEMICAL BIOLOGY (2019)
Frontiers in alopecia areata pathobiology research
Amos Gilhar et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Farzan Solimani et al.
FRONTIERS IN IMMUNOLOGY (2019)
Alopecia areata: a review of disease pathogenesis
F. Rajabi et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Gina A. Montealegre Sanchez et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Disease characteristics, clinical evaluation, and new perspectives on pathogenesis
Lauren C. Strazzulla et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
FDA approves Eli Lilly's baricitinib
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2018)
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
Katherine R. Tuttle et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors
Fabiola Atzeni et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
JAK inhibitors in dermatology: The promise of a new drug class
William Damsky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Alopecia areata
C. Herbert Pratt et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
Ali Jabbari et al.
EBIOMEDICINE (2015)
British Association of Dermatologists' guidelines for the management of alopecia areata 2012
A. G. Messenger et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Medical Progress Alopecia Areata
Amos Gilhar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity
Lynn Petukhova et al.
NATURE (2010)
Share Paper
